Search Results - "Fontenay, M."

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias by Itzykson, R, Kosmider, O, Cluzeau, T, Mansat-De Mas, V, Dreyfus, F, Beyne-Rauzy, O, Quesnel, B, Vey, N, Gelsi-Boyer, V, Raynaud, S, Preudhomme, C, Adès, L, Fenaux, P, Fontenay, M

“…The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS…”
Get full text

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells by Poulain, L, Sujobert, P, Zylbersztejn, F, Barreau, S, Stuani, L, Lambert, M, Palama, T L, Chesnais, V, Birsen, R, Vergez, F, Farge, T, Chenevier-Gobeaux, C, Fraisse, M, Bouillaud, F, Debeissat, C, Herault, O, Récher, C, Lacombe, C, Fontenay, M, Mayeux, P, Maciel, T T, Portais, J-C, Sarry, J-E, Tamburini, J, Bouscary, D, Chapuis, N

“…Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities. Here we decipher the interplay between…”
Get full text

Heat shock proteins: essential proteins for apoptosis regulation by Lanneau, D., Brunet, M., Frisan, E., Solary, E., Fontenay, M., Garrido, C.

“…•  Introduction •  Main HSPs •  HSPs, cell signalling and apoptosis ‐  HSPs’targets in upstream signalling pathways ‐  HSPs’targets at the mitochondrial level…”
Get full text

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms by Kosmider, O, Gelsi-Boyer, V, Slama, L, Dreyfus, F, Beyne-Rauzy, O, Quesnel, B, Hunault-Berger, M, Slama, B, Vey, N, Lacombe, C, Solary, E, Birnbaum, D, Bernard, O A, Fontenay, M

Get full text

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine by Valencia, A, Masala, E, Rossi, A, Martino, A, Sanna, A, Buchi, F, Canzian, F, Cilloni, D, Gaidano, V, Voso, M T, Kosmider, O, Fontenay, M, Gozzini, A, Bosi, A, Santini, V

“…The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after…”
Get full text

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes by Mathis, S, Chapuis, N, Debord, C, Rouquette, A, Radford-Weiss, I, Park, S, Dreyfus, F, Lacombe, C, Béné, M C, Kosmider, O, Fontenay, M, Bardet, V

“…Several groups have published flow cytometry scores useful for the diagnosis or prognosis of myelodysplastic syndromes (MDS), mainly based on the detection of…”
Get full text

Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein by Grignano, E., Cantero-Aguilar, L., Tuerdi, Z., Chabane, T., Vazquez, R., Johnson, N., Zerbit, J., Decroocq, J., Birsen, R., Fontenay, M., Kosmider, O., Chapuis, N., Bouscary, D.

“…Artemisinin is an anti-malarial drug that has shown anticancer properties. Recently, ferroptosis was reported to be induced by dihydroartemisinin (DHA) and…”
Get full text

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion by Toma, A, Kosmider, O, Chevret, S, Delaunay, J, Stamatoullas, A, Rose, C, Beyne-Rauzy, O, Banos, A, Guerci-Bresler, A, Wickenhauser, S, Caillot, D, Laribi, K, De Renzis, B, Bordessoule, D, Gardin, C, Slama, B, Sanhes, L, Gruson, B, Cony-Makhoul, P, Chouffi, B, Salanoubat, C, Benramdane, R, Legros, L, Wattel, E, Tertian, G, Bouabdallah, K, Guilhot, F, Taksin, A L, Cheze, S, Maloum, K, Nimuboma, S, Soussain, C, Isnard, F, Gyan, E, Petit, R, Lejeune, J, Sardnal, V, Renneville, A, Preudhomme, C, Fontenay, M, Fenaux, P, Dreyfus, F

“…After failure of erythropoiesis-stimulating agents (ESAs), lenalidomide (LEN) yields red blood cell (RBC) transfusion independence (TI) in 20–30% of lower-risk…”
Get full text

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias by Damm, F, Itzykson, R, Kosmider, O, Droin, N, Renneville, A, Chesnais, V, Gelsi-Boyer, V, de Botton, S, Vey, N, Preudhomme, C, Clavert, A, Delabesse, E, Park, S, Birnbaum, D, Fontenay, M, Bernard, O A, Solary, E

Get full text

AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages by Six, E, Lagresle-Peyrou, C, Susini, S, De Chappedelaine, C, Sigrist, N, Sadek, H, Chouteau, M, Cagnard, N, Fontenay, M, Hermine, O, Chomienne, C, Reynier, P, Fischer, A, André-Schmutz, I, Gueguen, N, Cavazzana, M

“…Reticular dysgenesis is a human severe combined immunodeficiency that is primarily characterized by profound neutropenia and lymphopenia. The condition is…”
Get full text

DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice by Scourzic, L, Couronné, L, Pedersen, M T, Della Valle, V, Diop, M, Mylonas, E, Calvo, J, Mouly, E, Lopez, C K, Martin, N, Fontenay, M, Bender, A, Guibert, S, Dubreuil, P, Dessen, P, Droin, N, Pflumio, F, Weber, M, Gaulard, P, Helin, K, Mercher, T, Bernard, O A

“…TEN-ELEVEN-TRANSLOCATION-2 (TET2) and DNA-METHYLTRANSFERASE-3A (DNMT3A), both encoding proteins involved in regulating DNA methylation, are mutated in…”
Get full text

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications by Damm, F, Thol, F, Kosmider, O, Kade, S, Löffeld, P, Dreyfus, F, Stamatoullas-Bastard, A, Tanguy-Schmidt, A, Beyne-Rauzy, O, de Botton, S, Guerci-Bresler, A, Göhring, G, Schlegelberger, B, Ganser, A, Bernard, O A, Fontenay, M, Heuser, M

Get full text

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia by Hospital, M-A, Jacquel, A, Mazed, F, Saland, E, Larrue, C, Mondesir, J, Birsen, R, Green, A S, Lambert, M, Sujobert, P, Gautier, E-F, Salnot, V, Le Gall, M, Decroocq, J, Poulain, L, Jacque, N, Fontenay, M, Kosmider, O, Récher, C, Auberger, P, Mayeux, P, Bouscary, D, Sarry, J-E, Tamburini, J

“…Acute myeloid leukemia (AML) with the FLT3 internal tandem duplication (FLT3-ITD AML) accounts for 20–30% of AML cases. This subtype usually responds poorly to…”
Get full text

Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study by Jestin, Matthieu, Tarfi, Sihem, Duchmann, Matthieu, Badaoui, Bouchra, Freynet, Nicolas, Tran Quang, Violaine, Sloma, Ivan, Droin, Nathalie, Morabito, Margot, Leclerc, Mathieu, Maury, Sébastien, Fenaux, Pierre, Solary, Eric, Selimoglu-Buet, Dorothée, Wagner-Ballon, Orianne

Get full text

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling by Kerdivel, G, Chesnais, V, Becht, E, Toma, A, Cagnard, N, Dumont, F, Rousseau, A, Fenaux, P, Chevret, S, Chapuis, N, Boeva, V, Fridman, W H, Fontenay, M, Kosmider, O

Get full text

Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies by Damm, F, Nguyen-Khac, F, Fontenay, M, Bernard, O A

“…Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion…”
Get full text

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? by Kosmider, Olivier, Passet, Marie, Santini, Valeria, Platzbecker, Uwe, Andrieu, Valérie, Zini, Gina, Beyne-Rauzy, Odile, Guerci, Agnès, Masala, Erico, Balleari, Enrico, Bulycheva, Ekaterina, Dreyfus, François, Fenaux, Pierre, Fontenay, Michaela, Park, Sophie

Get full text

Mitochondria in hematopoiesis and hematological diseases by Fontenay, M, Cathelin, S, Amiot, M, Gyan, E, Solary, E

“…Mitochondria are involved in hematopoietic cell homeostasis through multiple ways such as oxidative phosphorylation, various metabolic processes and the…”
Get full text

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML by Ettou, S, Audureau, E, Humbrecht, C, Benet, B, Jammes, H, Clozel, T, Bardet, V, Lacombe, C, Dreyfus, F, Mayeux, P, Solary, E, Fontenay, M

“…absent…”
Get full text

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia by Kosmider, O, Itzykson, R, Chesnais, V, Lasho, T, Laborde, R, Knudson, R, Gauthier, A, Merlevede, J, Ades, L, Morabito, M, Fontenay, M, Tefferi, A, Droin, N, Solary, E

Get full text